Zobrazeno 1 - 10
of 38
pro vyhledávání: ''
Autor:
Alexander Stein, Lisa Paschold, Joseph Tintelnot, Eray Goekkurt, Svenja-Sibylla Henkes, Donjete Simnica, Christoph Schultheiss, Edith Willscher, Marcus Bauer, Claudia Wickenhauser, Peter Thuss-Patience, Sylvie Lorenzen, Thomas Ettrich, Jorge Riera-Knorrenschild, Lutz Jacobasch, Albrecht Kretzschmar, Stefan Kubicka, Salah-Eddin Al-Batran, Anke Reinacher-Schick, Daniel Pink, Marianne Sinn, Udo Lindig, Wolfgang Hiegl, Axel Hinke, Susanna Hegewisch-Becker, Mascha Binder
Publikováno v:
JAMA Oncology.
In metastatic esophagogastric adenocarcinoma (EGA), the addition of programmed cell death 1 (PD-1) inhibitors to chemotherapy has improved outcomes in selected patient populations.To investigate the efficacy of trastuzumab and PD-1 inhibitors with cy
Autor:
Matthew H. G. Katz, Qian Shi, Jeff Meyers, Joseph M. Herman, Michael Chuong, Brian M. Wolpin, Syed Ahmad, Robert Marsh, Larry Schwartz, Spencer Behr, Wendy L. Frankel, Eric Collisson, James Leenstra, Terence M. Williams, Gina Vaccaro, Alan Venook, Jeffrey A. Meyerhardt, Eileen M. O’Reilly
Publikováno v:
JAMA Oncology. 8:1263
ImportanceNational guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear.ObjectiveTo compare treatment with neoadjuvant modified FOLFIRINOX (m
Autor:
Tiantian, Wang, Jie, Tang, Hongying, Yang, Rutie, Yin, Jingru, Zhang, Qi, Zhou, Ziling, Liu, Lanqin, Cao, Li, Li, Yi, Huang, Kui, Jiang, Wei, Wang, Fenglin, She, Ni, Guan, Zhiguo, Hou, Ning, Li, Lingying, Wu
Publikováno v:
JAMA Oncology. 8:1169
There are substantial unmet therapeutic needs in patients with platinum-resistant recurrent ovarian cancer (PROC), and novel therapeutic strategies should be explored.To evaluate the efficacy and safety of treatment with apatinib (a vascular endothel
Autor:
Pierre, Heudel, Jean-Sébastien, Frenel, Cécile, Dalban, Fernando, Bazan, Florence, Joly, Antoine, Arnaud, Cyril, Abdeddaim, Annick, Chevalier-Place, Paule, Augereau, Patricia, Pautier, Camille, Chakiba, Benoit, You, Laurence, Lancry-Lecomte, Gwenaelle, Garin, Virginie, Marcel, Jean Jacques, Diaz, Isabelle, Treilleux, David, Pérol, Michel, Fabbro, Isabelle, Ray-Coquard
Publikováno v:
JAMA Oncol
IMPORTANCE: Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors. The PI3K-AKT-mTOR pathway deregulation observed in endometrial cancer drives hormonal resistance, thus supporting the rationale of combining mTOR inhibit
Autor:
Robin L. Jones, Vinod Ravi, Andrew S. Brohl, Sant Chawla, Kristen N. Ganjoo, Antoine Italiano, Steven Attia, Melissa A. Burgess, Katherine Thornton, Lee D. Cranmer, Maggie Chon U. Cheang, Lingyun Liu, Liz Robertson, Bonne Adams, Charles Theuer, Robert G. Maki
Publikováno v:
JAMA Oncology. 8:740
Angiosarcoma is a rare sarcoma subtype with a poor outcome. Carotuximab plus pazopanib produced a median progression-free survival (PFS) of 7.8 months in pazopanib-naive patients with chemotherapy-refractory angiosarcoma in a phase 1/2 trial.To deter
Autor:
Kehl, Kenneth L., Zahrieh, David, Yang, Ping, Hillman, Shauna L., Tan, Angelina D., Sands, Jacob M., Oxnard, Geoffrey R., Gillaspie, Erin A., Wigle, Dennis, Malik, Shakun, Stinchcombe, Thomas E., Ramalingam, Suresh S., Kelly, Karen, Govindan, Ramaswamy, Mandrekar, Sumithra J., Osarogiagbon, Raymond U., Kozono, David
Publikováno v:
JAMA Oncol
IMPORTANCE: Standard treatment for resectable non–small cell lung cancer (NSCLC) includes anatomic resection with adequate lymph node dissection and adjuvant chemotherapy for appropriate patients. Historically, many patients with early-stage NSCLC
Autor:
Kelly Mousa, Keyur Mehta, Marcus Schmidt, Beate Rautenberg, Tessa Dibble, R. Charles Coombes, Robert Grieve, Janine Mansi, Holly Tovey, John M. S. Bartlett, Uwe Rhein, Carlo Palmieri, Elisabeth Murray, Lucy Kilburn, Sibylle Loibl, Abigail Evans, Andreas Makris, Robert E. Coleman, Annabel Borley, Catarina Alisa Kunze, Gunter von Minckwitz, Investigators, Judith M Bliss, Carsten Denkert, Jonathan Hicks, Xiao Lou Lu
Publikováno v:
JAMA Oncol
Importance Patients with breast cancer remain at risk of relapse after adjuvant therapy. Celecoxib has shown antitumor effects in preclinical models of human breast cancer, but clinical evidence is lacking. Objective To evaluate the role of celecoxib
Autor:
Keyur P. Patel, Prithviraj Bose, Nathan Fowler, Zeev Estrov, William Plunkett, Varsha Gandhi, Xuemei Wang, Marina Konopleva, Elias Jabbour, Michael J. Keating, Jan A. Burger, Nichole Cruz, Yesid Alvarado, Koichi Takahashi, Musa Yilmaz, Sa A. Wang, Wei Wang, Naveen Garg, Philip A. Thompson, Gautam Borthakur, Jeffrey L. Jorgensen, Naveen Pemmaraju, Ana Ayala, Chongjuan Wei, Maro Ohanian, Hagop M. Kantarjian, William G. Wierda, Rashmi Kanagal-Shamanna, Courtney D. DiNardo, Nitin Jain, Alessandra Ferrajoli, Tapan M. Kadia, Koji Sasaki
Publikováno v:
JAMA Oncol
Importance Oral targeted therapies have advanced the treatment of chronic lymphocytic leukemia (CLL). These therapies include Bruton tyrosine kinase inhibitors, used as monotherapy, and the Bcl-2 inhibitor venetoclax, typically combined with the CD20
Autor:
Nina A. Karaseva, Sukrut Shah, Lucjan Wyrwicz, Joseph Chao, Christian Caglevic, Kohei Shitara, Luis Villanueva, Eric Van Cutsem, Al B. Benson, Eray Goekkurt, Wasat Mansoor, Marcelo Garrido, Iveta Kudaba, Keun Wook Lee, Jeeyun Lee, Maria Alsina, Andrew H. Ko, Charles S. Fuchs, S. Peter Kang, Josep Tabernero, Hugo Castro, Hironaga Satake, Uma Kher, Yung-Jue Bang, Maria Ignez Braghiroli, Peter C. Enzinger, Zev A. Wainberg, Hyun Cheol Chung
Publikováno v:
JAMA Oncology. 6:1571
Importance Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. Objective To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus chemotherapy, or chemotherapy alo
Autor:
Michael Ghadimi, Ethan B. Ludmir, Ralf Hofheinz, Emmanouil Fokas, Bruce D. Minsky, Claus Rödel, Markus Diefenhardt
Publikováno v:
JAMA Oncology. 6:1416
Importance Despite numerous published phase 3 trials, the association of treatment adherence with outcomes for patients with rectal cancer remains largely unexplored. Objective To analyze the association of treatment adherence with disease-free survi